| KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA, Petra BLAHOVCOVA, Vit CAMPR, Vit PROCHAZKA, Ales OBR, Radek JAKSA, Jana KUNTSCHEROVA, Ludmila BOUDOVA, Roman KODET, Andrea JANÍKOVÁ a Marek TRNENY. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. American Journal of Hematology. Hoboken: John Wiley & Sons, 2019, roč. 94, č. 2, s. "E50"-"E53", 4 s. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.25362. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1612157,
author = {Klener, Pavel and Šálek, David and Pytlik, Robert and Mocikova, Heidi and Forsterova, Kristina and Blahovcova, Petra and Campr, Vit and Prochazka, Vit and Obr, Ales and Jaksa, Radek and Kuntscherova, Jana and Boudova, Ludmila and Kodet, Roman and Janíková, Andrea and Trneny, Marek},
article_location = {Hoboken},
article_number = {2},
doi = {http://dx.doi.org/10.1002/ajh.25362},
keywords = {FOLLOW-UP; IMMUNOCHEMOTHERAPY},
language = {eng},
issn = {0361-8609},
journal = {American Journal of Hematology},
title = {Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation},
url = {http://dx.doi.org/10.1002/ajh.25362},
volume = {94},
year = {2019}
}
TY - JOUR
ID - 1612157
AU - Klener, Pavel - Šálek, David - Pytlik, Robert - Mocikova, Heidi - Forsterova, Kristina - Blahovcova, Petra - Campr, Vit - Prochazka, Vit - Obr, Ales - Jaksa, Radek - Kuntscherova, Jana - Boudova, Ludmila - Kodet, Roman - Janíková, Andrea - Trneny, Marek
PY - 2019
TI - Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
JF - American Journal of Hematology
VL - 94
IS - 2
SP - "E50"-"E53"
EP - "E50"-"E53"
PB - John Wiley & Sons
SN - 03618609
KW - FOLLOW-UP
KW - IMMUNOCHEMOTHERAPY
UR - http://dx.doi.org/10.1002/ajh.25362
L2 - http://dx.doi.org/10.1002/ajh.25362
N2 - Mantle cell lymphoma (MCL) is still considered to be an incurable subtype of B-NHL, but the outcome is improving and the implementation of anti-CD20 rituximab and high-dose cytarabine (HDAC) into E50 CORRESPONDENCE induction therapy, consolidation with high-dose therapy and autologous stem cell transplant (ASCT), and rituximab maintenance (RM) are currently considered standard approaches for all transplant-eligible patients. Recently, progression free survival (PFS) and overall survival (OS) benefit of RM were confirmed in patients (pts) with MCL treated with R-DHAP and ASCT.1 Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066), we analyzed outcome of 143 consecutive patients with newly diagnosed MCL treated with the Nordic MCL2 protocol followed by ASCT and RM or observation.2,3 The study was approved by the Ethics Committee of the Charles University General Hospital in Prague under number 1816/15S-IV. Further details are described in the Supplemental Methods.
ER -
KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA, Petra BLAHOVCOVA, Vit CAMPR, Vit PROCHAZKA, Ales OBR, Radek JAKSA, Jana KUNTSCHEROVA, Ludmila BOUDOVA, Roman KODET, Andrea JANÍKOVÁ a Marek TRNENY. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2019, roč.~94, č.~2, s.~''E50''-''E53'', 4 s. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.25362.
|
